AARDEX Group Partners with Pill Connect

Belgium-based AARDEX Group, a leader in medication adherence solutions, has entered a strategic partnership with Pill Connect Ltd, an English company specializing in the design, development and manufacture of innovative medical devices for dispensing solid oral dose medication.

The collaboration will link AARDEX’s proprietary Medication Event Monitoring System (MEMS) with Pill Connect’s add-on solutions for drug delivery devices. The combined system has significant potential to radically influence patients’ adherence performance.

Through this strategic alliance, AARDEX will reinforce its portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers. There are significant benefits to be gained from ecosystems that seamlessly measure and analyze patient adherence to medications in clinical trials. The successful management of this is supported by research settings and professional healthcare systems. The first initiative will integrate Pill Connect’s smart dosing system with AARDEX’s MEMS Adherence Software (MEMS AS) for medicines delivered in solid oral dose form. The collaboration will start in academic research, followed by drug development clinical trials, and then extended to commercialized drugs and real-life conditions. 

David Dalla Vecchia, CEO and financial lead of AARDEX Group, commented, “Smart packaging is one of the most reliable ways to accurately measure, describe, manage and influence patient adherence in relation to medication. It highly correlates with patient behavior, making the results highly valuable. It is a proven way to minimize risk while being a seamless experience for patients. The objective is to support an unbiased and precise measure of medication adherence in key therapy areas, not only for commercialized drugs and real-life conditions, but also clinical trials and drug efficacy. This partnership will also be pivotal in enhancing the impact of academic research findings.”

James Burnstone, CEO of Pill Connect Ltd added, “Managing patient compliance can make the difference between failed and successful clinical trials. The combination of Pill Connect’s smart dosing systems with the AARDEX MEMS AS system ensures the precise capture and analysis of data for clinical trials and adherence monitoring. We are delighted to be collaborating to bring these solutions to our customers. For clinical trials, the integration of this kind of tool will improve the speed and accuracy of medication adherence assessment and intervention efficacy and potentially decrease the rate of unnecessary mediation, bolstering success at every level.”